The Filing Desk

Krystal Biotech vs Twist Bioscience

Krystal Biotech KRYS · Twist Bioscience TWST · Biotechnology

Krystal Biotech reported revenue of $389 million in fiscal 2025, about the same as Twist Bioscience's $377 million in fiscal 2025. Krystal Biotech's revenue grew 33.9% in its latest year, and Twist Bioscience's grew 20.3%. Krystal Biotech had an operating margin of 41.5%, against -36.2% at Twist Bioscience. Free cash flow was $189 million at Krystal Biotech and −$76 million at Twist Bioscience. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.

Side by side

Krystal BiotechTwist Bioscience
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Sep 30, 2025
Revenue$389M$377M
Revenue growth33.9%20.3%
Revenue growth a year, last 5 years—33.1%
Gross margin—50.7%
Operating margin41.5%−36.2%
Net margin52.6%−20.6%
Free cash flow$189M−$76M
Free cash flow margin48.5%−20.1%
Return on capital43.6%—
Net debt to EBITDA−5.0x—
Dividends and buybacks$0M$0M
Change in diluted share count0.7%3.1%
Last close$305.23$111.60
P/E at the last close41.4×—
Insider trades, last 12 monthssold $105.3 millionsold $126.1 million
Piotroski F-score5 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Krystal BiotechTwist Bioscience
Operating margin
Percent of revenue
Krystal BiotechTwist Bioscience
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Krystal BiotechTwist Bioscience

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Krystal Biotech and Twist Bioscience pages.